Aerie Pharmaceuticals (AERI) Given a $77.00 Price Target by Cantor Fitzgerald Analysts

Aerie Pharmaceuticals (NASDAQ:AERI) has been assigned a $77.00 price objective by equities researchers at Cantor Fitzgerald in a report issued on Monday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 32.19% from the company’s previous close.

A number of other equities analysts have also weighed in on the company. Guggenheim initiated coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They set a “buy” rating and a $80.00 target price on the stock. Zacks Investment Research lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Mizuho reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. Cowen reiterated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Thursday, October 5th. Finally, Canaccord Genuity set a $73.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and an average target price of $72.00.

Shares of Aerie Pharmaceuticals (NASDAQ AERI) traded down $0.05 during midday trading on Monday, hitting $58.25. The stock had a trading volume of 1,120,233 shares, compared to its average volume of 508,423. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. Aerie Pharmaceuticals has a one year low of $35.50 and a one year high of $66.60.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after buying an additional 766,300 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Aerie Pharmaceuticals by 25.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 550,275 shares of the company’s stock valued at $26,743,000 after purchasing an additional 113,320 shares in the last quarter. Columbus Circle Investors boosted its holdings in shares of Aerie Pharmaceuticals by 41.0% in the 3rd quarter. Columbus Circle Investors now owns 519,806 shares of the company’s stock valued at $25,263,000 after purchasing an additional 151,133 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Aerie Pharmaceuticals by 6.6% in the 2nd quarter. Northern Trust Corp now owns 405,116 shares of the company’s stock valued at $21,289,000 after purchasing an additional 25,254 shares in the last quarter. Finally, Sectoral Asset Management Inc boosted its holdings in shares of Aerie Pharmaceuticals by 3.4% in the 2nd quarter. Sectoral Asset Management Inc now owns 402,674 shares of the company’s stock valued at $21,161,000 after purchasing an additional 13,251 shares in the last quarter.

WARNING: “Aerie Pharmaceuticals (AERI) Given a $77.00 Price Target by Cantor Fitzgerald Analysts” was reported by American Market News and is the property of of American Market News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/19/aerie-pharmaceuticals-aeri-given-a-77-00-price-target-by-cantor-fitzgerald-analysts.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).